Study Review – Ruxolitinib in intermediate-1 risk myelofibrosis: a summary of recent evidence

This review summarises and discusses the findings of several recent independent studies looking at patients
with intermediate-1 risk myelofibrosis (MF).

Independent commentary is provided by Dr David Ross, a Consultant Haematologist in SA Pathology with clinical appointments at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide, Australia


Please login below to download this issue (PDF)